London, 1st September 2003
Cancer Research Technology announces the appointment of Dr Andy Richards and Dr Celia Caulcott as Non-Executive Directors to the Board
Cancer Research Technology Ltd. (CRT) is pleased to announce the appointment of Dr Andy Richards and Dr Celia Caulcott to its board of Directors. Dr Andy Richards, formerly a founder and Executive Director of Chiroscience plc (part of Celltech Group), is now a director and business angel investor for a number of biotechnology companies - Arakis Ltd, Biowisdom Ltd, Vectura Ltd, Amedis Pharmaceuticals, Sirus Pharmaceuticals Ltd and Daniolabs Ltd. As a founder member of Cambridge Angels, Dr Richards is an expert in investing in, creating, advising and building start-up companies. Dr Celia Caulcott is a Senior Biotechnology Scientist and Consultant with over 20 years experience gained in the biotechnology and pharmaceutical industry. Dr Caulcott has a wealth of experience of technology transfer between academia and industry and expertise in the application and exploitation of human and pathogen genomics. She also has considerable experience of the major UK science funding councils.
Dr John Tooze and Mr James Davidson, both Executive Directors of Cancer Research UK, are stepping down from CRT's Board.
Dr Melanie Lee, Chairman of CRT, said: "We are delighted to welcome Andy and Celia to the CRT Board. CRT has a very important and exciting future ahead of it - a future that will benefit greatly from the expertise and guidance of Andy and Celia as part of a vibrant and effective Board of Directors. We also thank John and James for their support, commitment and advice over the past years"
Notes to editors:
Cancer Research Technology Limited
Cancer Research Technology (CRT) is a specialist technology transfer company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly-owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with cancer scientists and their institutes to protect the intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies.
Further information about CRT can be obtained from:
Nick J. Wells DPhil
Marketing and Business Manager
Cancer Research Technology Limited
Sardinia House
Sardinia Street
London WC2A 3NL
Tel: +44 (0)20 7269 3640
Fax: +44 (0)20 7269 3641
Email: nwells@cancertechnology.com
|
